Tabula Rasa Healthcare (TRHC) PT Raised to $7 at RBC Capital, 'Preannounces Better-Than-Expected Q4'

RBC Capital analyst Sean Dodge raised the price target on Tabula Rasa Healthcare (NASDAQ: TRHC) to $7.00 (from $6.00) while maintaining a Outperform rating.

The analyst comments "This morning, TRHC pre-announced Q4 revenue 5.1% above consensus, bringing the FY revenue growth target to ~15%. We view this as an encouraging update heading into '23, particularly when combined with (1) the also-recently-announced (after Q3 results/most recent guidance) commercial win that should drive incremental growth in '23 and (2) what appears to be a stabilizing/improving PACE enrollment growth rate YoY. Raising PT to $7 (from $6)."

You May Also Be Interested In

• Monopar Therapeutics (MNPR) PT Raised to $133 at BTIG
• Riskified Ltd. (RSKD) PT Raised to $5.50 at Goldman Sachs
• Lemon Tree Hotels (LEMONTRE:IN) PT Raised to INR180 at Macquarie